Citadel Advisors
RVPH

Citadel Advisors’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Citadel Advisors’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-43,610
Closed -$243K – 14071
2025
Q4 		$243K Buy
43,610
+22,770
+109% +$253K ﹤0.01% 10616
2025
Q3 		$154K Sell
20,840
-1,745
-8% -$14.8K ﹤0.01% 11514
2025
Q2 		$172K Sell
22,585
-1,145
-5% -$17.8K ﹤0.01% 10823
2025
Q1 		$453K Buy
23,730
+6,160
+35% +$194K ﹤0.01% 8692
2024
Q4 		$636K Buy
17,570
+14,570
+486% +$406K ﹤0.01% 8013
2024
Q3 		$86.4K Sell
3,000
-2,305
-43% -$51.2K ﹤0.01% 11313
2024
Q2 		$136K Sell
5,305
-785
-13% -$35.7K ﹤0.01% 10489
2024
Q1 		$460K Buy
6,090
+3,475
+133% +$275K ﹤0.01% 8572
2023
Q4 		$269K Sell
2,615
-1,060
-29% -$95.1K ﹤0.01% 9368
2023
Q3 		$359K Buy
3,675
+2,170
+144% +$202K ﹤0.01% 8786
2023
Q2 		$176K Sell
1,505
-1,875
-55% -$238K ﹤0.01% 10080
2023
Q1 		$283K Sell
3,380
-1,395
-29% -$122K ﹤0.01% 9494
2022
Q4 		$406K Sell
4,775
-2,515
-34% -$192K ﹤0.01% 8678
2022
Q3 		$232K Buy
7,290
+6,470
+789% +$179K ﹤0.01% 10104
2022
Q2 		$18K Buy
820
+105
+15% +$3.68K ﹤0.01% 12440
2022
Q1 		$35K Buy
+715
New +$28.5K ﹤0.01% 13021

Other funds holding RVPH

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's RVPH Position: Q1 2026 in Review

Citadel Advisors sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q1 2026, closing a stake of 27,732 shares — an estimated $155K sold.

Citadel Advisors first reported a position in RVPH in Q1 2021 and held it in 9 quarters. The position peaked at $488K in Q2 2023. 35 funds tracked by Wall St. Rank hold RVPH as of Q1 2026.

  • Citadel Advisors reported no remaining REVIVA PHARMA HLDGS INC position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 27,732 REVIVA PHARMA HLDGS INC shares in Q1 2026, an estimated $155K.
  • Citadel Advisors first reported a position in REVIVA PHARMA HLDGS INC in Q1 2021 and held it in 9 quarters.
  • Citadel Advisors's REVIVA PHARMA HLDGS INC position peaked at $488K in Q2 2023.
  • 35 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.